VALNEVA: Valneva Reports Full Year 2022 Results and Provides Corporate Updates

Total revenues of €361.3 million in 2022 compared to €348.1 million in 2021 Driven by product sales of €114.8 million (82.3% increase compared to 2021), including €85.2 million of travel vaccine sales

Related Keywords

Japan ,Finland ,Australia ,Thailand ,France ,New Zealand ,Sweden ,United Kingdom ,United Arab Emirates ,Denmark ,Austria ,Germany ,Bulgaria ,United States ,Brazil ,Bahrain ,Canada ,Switzerland ,America ,Scotland ,Kingdom Of Bahrain ,Japanese ,Deerfield Orbimed ,Instituto Butantan ,Joshua Drumm ,Vivalis Intercell ,Tropical Disease Priority Review Voucher Program ,Vaccines Announce European Partnership For Marketing ,Global Communications ,Drug Administration ,European Commission For Valneva Inactivated ,Pan American Health Organization ,European Medicines Agency ,Pfizer ,Us Department Of Defense ,European Union Member States ,European Commission ,European Union ,Deerfield Management Company Orbimed ,Coalition For Epidemic Preparedness Innovations ,Euronext Paris ,Chief Financial Officer ,Biologics License Application ,Prescription Drug User Fee Act ,Epidemic Preparedness Innovations ,Breakthrough Therapy ,Priority Review Voucher ,North America ,Fast Track ,Against Lyme ,Outdoor Recreationists ,Good Clinical Practice ,United Arab ,Valneva Sweden ,Deerfield Management Company ,European Investor ,Global Investor Relations ,Announces Closing ,Global Offering ,Announces Upsized Financing Arrangement ,Funds Deerfield ,Chikungunya Vaccine License Application ,Priority Review ,Initiates Rolling Submission ,License Application ,Single Shot Chikungunya Vaccine Candidate ,Successfully Completes Pivotal Phase ,Single Shot Chikungunya Vaccine ,Reports Positive ,Month Antibody Persistence Data ,Announces Initiation ,Adolescent Phase ,Completes Enrollment ,Disease Priority Review Voucher Program ,Pfizer Report Six Month Antibody Persistence Data ,Lyme Disease Vaccine Candidate ,Valneva Initiate Phase ,Pfizer Report Further Positive Phase ,Including Booster Response ,Valneva Issue Update ,Trial Evaluating Lyme Disease Vaccine Candidate ,Pfizer Enter ,Equity Subscription Agreement ,Update Terms ,Collaboration Agreement ,Fifth Disease ,Prescribing Information ,Medication Guide ,Enterotoxigenic Escherichia ,Receives Marketing Authorization ,Inactivated Whole Virus ,Receives Conditional Marketing Authorization ,Receives Emergency Use Authorization ,Confirms Amendment ,Advance Purchase Agreement ,Provides Clinical ,Regulatory Updates ,Announce European Partnership ,Diese Gold Aktie ,Sichern Sie ,Valneva ,Reports ,Bull ,Ear ,022 ,Results ,Rovides ,Corporate ,Updates ,